Project Grant R01CA285526
Award Date
8/9/24
Completion Date
7/31/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), provides $632,906 to Tulane University to conduct research on a novel role for the androgen receptor (AR) in prostate cancer progression and therapeutic resistance. The research aims to elucidate how AR's RNA-binding activity, rather than just its classical DNA-binding function, regulates the expression of key splicing factors that drive prostate cancer progression....
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
This Project Grant award of $371,719 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the University of Pennsylvania to characterize epigenetic targets in prostate cancer. The key objectives are to: Gain mechanistic insights into how the histone methyltransferase NSD2 influences the chromatin landscape to facilitate the assembly of the androgen receptor (AR) enhanceosome complex and enhance AR-driven transcription in prostate cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,902.00 to the University of Massachusetts Boston to conduct research aimed at overcoming lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key research objectives are to determine if expression of the FOXA2 transcription factor drives prostate cancer cells into a multilineage transition state, investigate how FOXA2 collaborates with the AP-1...
This $1,082,472 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Emory University to determine the molecular mechanisms underlying luminal-to-neuroendocrine transdifferentiation (NET) in prostate cancer. The 5-year project aims to: 1) evaluate whether NKX2-1's DNA binding and interaction with FOXA2 are required for FOXA2-induced NET, 2) assess if TET1 induction and regional DNA demethylation are necessary for...
This $116,720 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will fund research to investigate the molecular basis of the interactions between the protein ABI1 and the androgen receptor (AR) in prostate cancer. The award will be used by the Research Foundation for the State University of New York, doing business as Upstate Medical Center, to conduct biophysical studies to elucidate how ABI1 binds to AR and affects its DNA...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research aimed at overcoming resistance to radiopharmaceutical therapy (RPT) in prostate cancer. The $404,972 award, effective August 1, 2025 through July 31, 2027, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how the tumor microenvironment, specifically the enzyme ENPP1, can limit the immune-activating effects of PSMA-targeted RPT....
The National Cancer Institute (NCI) awarded a $1,948,592 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Washington University to conduct a Phase 1 clinical trial assessing the safety, tolerability, pharmacokinetics, and anti-tumor activity of the novel ACK1 inhibitor (R)-9B in patients with castration-resistant prostate cancer (CRPC). The grant period runs from August 15, 2024 to July 31, 2029. The study aims to evaluate (R)-9B's ability to overcome CRPC resistance...